Industry Analysis Examines How FDA's First Oral GLP-1 Approval, Published Clinical Trial Data, and Evolving Telehealth Access ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

Reuters spoke to three-dozen people inside the industry including retailers, drugmakers, telehealth providers and investors to show how the weight-loss sector is shifting to better meet consumers ...

Ask executives in the healthcare industry about the future market for weight-loss drugs and the analogies are telling: ...

Novo Nordisk is lowering prices of its top-selling obesity drug Wegovy in China, the Danish drugmaker said on Monday, as it ...

Discover S&P 500 forecasts for 2025-2026, key market risks, and why pharmaceuticals may outperform. Click for more on my view ...

Before The Motley Fool, Prosper wrote about investing topics ranging from stock market news to private equity for various ...

Claims about deportations, the Department of Government Efficiency, and someone fainting in the White House were among the mistruths that kept PolitiFact busy in 2025 — and they featured in some of ...

Novo Nordisk A/S cut the price of its obesity drug Wegovy in China as the Danish drugmaker gears up for a potential flood of ...

The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. Other ...